NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.03. The biopharmaceutical company had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.44 million. Acceleron Pharma had a negative net margin of 353.57% and a negative return on equity of 30.79%. The firm's revenue was up 27.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.63) EPS. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

12 brokerages have issued 1-year price objectives for Acceleron Pharma's shares. Their forecasts range from $45.00 to $88.00. On average, they anticipate Acceleron Pharma's share price to reach $60.82 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Press coverage about XLRN stock has been trending very positive on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a media sentiment score of 3.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Acceleron Pharma.

Acceleron Pharma saw a decline in short interest in December. As of December 13th, there was short interest totalling 4,230,000 shares, a decline of 6.8% from the November 28th total of 4,540,000 shares. Based on an average daily volume of 359,500 shares, the days-to-cover ratio is presently 11.8 days. Currently, 9.4% of the shares of the stock are sold short. View Acceleron Pharma's Current Options Chain.

Some companies that are related to Acceleron Pharma include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Incyte (INCY), LogicBio Therapeutics (LOGC), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Intel (INTC), Corcept Therapeutics (CORT), Exelixis (EXEL) and Bausch Health Companies (BHC).

Acceleron Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.19%), Neville Rodie & Shaw Inc. (0.04%), Zeke Capital Advisors LLC (0.02%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Zeke Capital Advisors LLC and Nisa Investment Advisors LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $56.14.

Acceleron Pharma has a market capitalization of $2.98 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]